Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model

Camille Guillerey,Kyohei Nakamura,Andrea C Pichler,Deborah Barkauskas,Sophie Krumeich,Kimberley Stannard,Kim Miles,Heidi Harjunpää,Yuan Yu,Mika Casey,Alina I Doban,Mircea Lazar,Gunter Hartel,David Smith,Slavica Vuckovic,Michele Wl Teng,P Leif Bergsagel,Marta Chesi,Geoffrey R Hill,Ludovic Martinet,Mark J Smyth

DOI: https://doi.org/10.1172/jci.insight.125932

IF: 9.4958

2019-06-13

JCI Insight

Abstract:Immunotherapy holds promise for multiple myeloma (MM) patients but little is known about how MM-induced immunosuppression influences response to therapy. Here, we investigated the impact of disease progression on immunotherapy efficacy in the Vk*MYC mouse model. Treatment with agonistic anti-CD137 (4-1BB) mAbs efficiently protected mice when administered early but failed to contain MM growth when delayed more than three weeks after Vk*MYC tumor cell challenge. The quality of CD8+ T cell response to CD137 stimulation was not altered by the presence of MM, but CD8+ T cell numbers were profoundly reduced at the time of treatment. Our data suggest that an insufficient ratio of CD8+ T cells over MM cells (CD8/MM) accounts for the loss of anti-CD137 mAb efficacy. We established serum M-protein levels prior to therapy as a predictive factor of response. Moreover, we developed an in silico model to capture the dynamic interactions between CD8+ T cells and MM cells. Finally, we explored two methods to improve the CD8/MM ratio: anti-CD137 mAb immunotherapy combined with Treg-depletion or administered after chemotherapy treatment with cyclophosphamide or melphalan efficiently reduced MM burden and prolonged survival. Altogether, our data indicate that consolidation treatment with anti-CD137 mAbs might prevent MM relapse.